Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Genetics primarily determine hair loss, not lifestyle factors like diet, exercise, or habits. Treatments like finasteride and minoxidil are recommended, but ultimately, happiness should not depend on hair.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

Nutrafol, a hair loss supplement, has limited and potentially biased research, with one study showing a 10% increase in hair count for women after 6 months but no significant results for men. The user concludes that cheaper, well-studied options like minoxidil may be more effective, especially for men, given the lack of evidence supporting Nutrafol.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

Low folic acid may worsen side effects of finasteride. Consult a doctor for personalized advice.

The user maintained their hair over five years using finasteride and recently started using Rogaine to improve the front. They experienced no side effects and are satisfied with the results, considering the alternative of more significant hair loss.

The conversation discusses using finasteride for 2 years and dutasteride for 6 months to treat hair loss, resulting in significant improvement. The user did not experience side effects and did not use other treatments like minoxidil, supplements, or micro-needling.

After 2 months of using Minoxidil and finasteride, OP noticed fuller hair, confirmed by their wife's observation. OP is pleased with the progress, though the change isn't drastic.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

A user shared their experience with finasteride, reporting severe side effects like erectile dysfunction and watery semen, which improved after stopping the medication. They emphasized the risks of finasteride and decided not to resume its use despite hair loss stabilization.

A 25-year-old male is concerned about his blood test results, particularly the low percentage of free testosterone, and is questioning whether starting finasteride for hair loss might worsen this issue. He also notes a slight vitamin D deficiency and lack of sleep before the test.

A humorous discussion about hair regrowth using finasteride, with jokes about telekinesis and tiny ants. The conversation is satirical, with users making light of hair loss treatments.

Dutasteride at 0.5 mg and 2.5 mg doses may eventually yield similar hair growth results over time, with 0.5 mg being sufficient for many users. Higher doses may not significantly increase benefits and could lead to diminished returns.

The conversation revolves around the experiences of different individuals with hair loss treatments like Minoxidil, Finasteride, and RU58841. The discussion includes various perspectives on the effects of these treatments, the importance of hair for self-esteem and attractiveness, and the influence of significant others on the decision to use or stop using these treatments.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A woman who has been experiencing hair loss for several years, and her question of whether there is any benefit to getting a biopsy to check if it's AGA or diffuse alopecia areata when no cure or very effective treatment exists. Treatments such as spironolactone and Minoxidil/finasteride/RU58841 have previously been discussed.

Topical finasteride as a potential alternative to oral finasteride for reducing DHT levels on the scalp with fewer side effects, and other hair loss treatments such as minoxidil.

Finasteride raises total testosterone but lowers free testosterone, which is important for male health. Users report mixed experiences with their fitness levels and blood test results after using finasteride.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

A user shared their 1.5-year experience using 0.25mg finasteride daily for hair loss, noting significant hair quality improvements and reduced scalp itch but mild erectile dysfunction. They managed side effects with daily 2.5mg Cialis and 5mg citrulline and plan to continue this routine.

The conversation discusses hair loss treatments, specifically the use of finasteride, dutasteride, and RU58841. The user is seeking alternatives after finasteride failed to stop hair loss, with suggestions to try dutasteride or consider RU58841 under caution.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

The user is experiencing a strange hair loss pattern despite using dutasteride for 3 years and minoxidil with tretinoin for 1.5 years. They recently added microneedling and are considering a scalp biopsy to understand the cause.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.